Sunvozertinib, also known as DZD9008, is an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor. Sunvozertinib shows activity against EGFRexon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase I clinical studies, sunvozertinib was tolerated up to 400 mg once daily.
For research use only. We do not sell to patients.
Name | Sunvozertinib ( DZD 9008 ) |
---|---|
Iupac Chemical Name | (R)-N-(5-((4-((5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)phenyl)amino)pyrimidin-2-yl)amino)-2-(3-(dimethylamino)pyrrolidin-1-yl)-4-methoxyphenyl)acrylamide |
Synonyms | Sunvozertinib ; DZD 9008 ; DZD-9008 ; DZD9008 ; |
Molecular Formula | C29H35ClFN7O3 |
Molecular Weight | 584.08 |
Smile | C(C)(O)C)=N2)=C(OC)C=C1N4C[C@H](N(C)C)CC4)=O |
InChiKey | BTMKEDDEMKKSEF-QGZVFWFLSA-N |
InChi | InChI=1S/C29H35ClFN7O3/c1-7-27(39)34-22-14-23(25(41-6)15-24(22)38-11-9-17(16-38)37(4)5)35-28-32-10-8-26(36-28)33-21-13-19(30)20(31)12-18(21)29(2,3)40/h7-8,10,12-15,17,40H,1,9,11,16H2,2-6H3,(H,34,39)(H2,32,33,35,36)/t17-/m1/s1 |
CAS Number | 2370013-12-8 |
Related CAS | 2370013-49-1 ( S ) ; 2370013-12-8 ( R ) |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | Off-white to light-yellow solid |
---|---|
Purity | ≧98.0% |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Solubility | Soluble in DMSO |
Handling | Refer to MSDS |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
HS Code | 2934200090 |
Targets | EGFR tyrosine kinase inhibitor |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |